[News in the treatment of rheumatic diseases]

Rheumatic diseases are frustrating issue for the rheumatologists because ethiologic remedy is still missing and much more, they are great socio-economic burden for patients and society. In the last 10 years there was bustling endeavour in creating new products with exact known action. This article deal the new options to treat rheumatoid arthritis with leflunomide, infliximab, etanercept and anakinra and osteoarthritis with hyaluronan, diacerhein, glucosamino sulphate, chondroitin sulphate and avocado/soya unsaponifiables. In particular patients all mentioned products have their place in the treatment plan but critical risk-benefit assessment is needed.